title: Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province.
abstract: OBJECTIVE
  We analyzed the clinical features of 417 patients with hemophilia from 11 Hemophilia Treatment Centers in Shanxi Province (SP) in China.
  
  
  METHODS
  We used data collected in the national registry of hemophilia A and hemophilia B in SP from January 2010 to December 2013.
  
  
  RESULTS
  Ratio of hemophilia A:hemophilia B patients was 5:1, of which 48% (200/417) were severe, 31% (129/417) moderate and 21% (88/417) mild. Episodes of joint bleeding occurred in 73% (305/417) of patients. Only 4% (15/417) of patients received tertiary prophylaxis. Three percent of patients (2/72) were hepatitis B virus-Ab positive, and 7% (5/72) of patients were hepatitis C virus-Ab positive. The incidence of inhibitors was 6% (11/182).
  
  
  CONCLUSIONS
  The ability to manage hemophilia in SP remains suboptimal. However, due to limited data, the evaluation and extrapolation of large hemophilia populations in SP are restricted, therefore, further studies with a large cohort are needed.
authors.affiliation: Nursing College of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhao
authors.forename: Linhua
authors.initials: L
authors.lastname: Yang
authors.forename: Chao
authors.initials: C
authors.lastname: Long
authors.forename: Yulin
authors.initials: Y
authors.lastname: Guo
authors.forename: Ruihong
authors.initials: R
authors.lastname: Wu
authors.forename: Xiue
authors.initials: X
authors.lastname: Liu
authors.forename: Xiuyu
authors.initials: X
authors.lastname: Qin
authors.forename: Hongzheng
authors.initials: H
authors.lastname: Liang
authors.forename: Zhiguang
authors.initials: Z
authors.lastname: Duan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D005164:Factor IX / Q000235:genetics; D005169:Factor VIII / Q000235:genetics; D005260:Female; D006395:Hemarthrosis / Q000209:etiology; D006467:Hemophilia A / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D002836:Hemophilia B / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010346:Patient Care Management; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D005169:Factor VIII; D005164:Factor IX
keywords: China; clotting; hemophilia; inhibitors; transfusion-transmitted infections